Bone Marrow-Derived Mesenchymal Stem Cells Restored High-Fat-Fed Induced Hyperinsulinemia in Rats at Early Stage of Type 2 Diabetes Mellitus

Gongchi Li1, Han Peng2, Shen Qian3, Xinhua Zou4, Ye Du4, Zhi Wang4, Lijun Zou4, Zibo Feng4, Jing Zhang4, Youpeng Zhu4, Huamin Liang5,6, and Binghui Li4

Abstract
Numerous studies have proposed the transplantation of mesenchymal stem cells (MSCs) in the treatment of typical type 2 diabetes mellitus (T2DM). We aimed to find a new strategy with MSC therapy at an early stage of T2DM to efficiently prevent the progressive deterioration of organic dysfunction. Using the high-fat-fed hyperinsulinemia rat model, we found that before the onset of typical T2DM, bone marrow-derived MSCs (BM-MSCs) significantly attenuated rising insulin with decline in glucose as well as restored lipometabolic disorder and liver dysfunction. BM-MSCs also favored the histological structure recovery and proliferative capacity of pancreatic islet cells. More importantly, BM-MSC administration successfully reversed the abnormal expression of insulin resistance-related proteins including GLUT4, phosphorylated insulin receptor substrate 1, and protein kinase Akt and proinflammatory cytokines IL-6 and TNFα in liver. These findings suggested that MSCs transplantation during hyperinsulinemia could prevent most potential risks of T2DM for patients.

Keywords
mesenchymal stem cells, insulin resistance, high fat diet, type 2 diabetes mellitus, lipometabolic disorder

Introduction
Diabetes mellitus (DM) is a major risk factor for many diseases such as ischemic heart disease and stroke, chronic kidney disease, and blindness among adults1–3. Long-term high-fat food is one of the causes leading to insulin resistance (IR) followed by a compensatory hyperinsulinemia4–6. Because of the high secretory activity, β cells are constantly exposed to various kinds of stresses, such as glucolipotoxicity and oxidative stress7,8. Eventually, this results in β-cell death, which is characterized as typical type 2 diabetes mellitus (T2DM) characterized by hyperinsulinemia and hyperglycemia9,10. IR might last for 10 years before the onset of β-cell dysfunction and diabetes11; therefore, alleviation of IR at the early stage could be the most efficient approach to prevent progressive and inexorable β-cell dysfunction. Clinical treatment of T2DM including oral antidiabetic drugs and exogenous supply of insulin could reverse neither IR nor β-cell dysfunction12,13.

Mesenchymal stem cells (MSCs) can differentiate into different types of connective tissue cells, which have the

1 Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
3 School of Foreign Studies of Zhongnan University of Economics and Law, Wuhan, China
4 Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Chronic Wound and Diabetic Foot Clinical Research Center, Wuhan, China
5 Department of Physiology, Hubei Key Laboratory of Drug Target Research and Pharmacodynamic Evaluation, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, China
6 Institute of Brain Research, Huazhong University of Science and Technology, Wuhan, China

Submitted: November 7, 2019. Accepted: December 9, 2019.

Corresponding Authors:
Binghui Li, 39 Lake Road, East Lake, Ecological Scenic, Wuhan 430077, Hubei, China. Email: libinghui2006@sina.com; Huamin Liang, Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China. Email: lianghuamin76@163.com

© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0963689720904628
journals.sagepub.com/home/cll

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
capability to produce bone, adipose, and cartilage, modulate the local environment, activate endogenous progenitor cells, and secrete various factors\textsuperscript{14,15}. Through clinical trials and mouse models, they have successfully restored insulin and stimulated glucose uptake in typical T2DM\textsuperscript{16–20}. However, most effects are based on regenerating injured pancreatic tissues and anti-inflammatory or paracrine effects\textsuperscript{16–20}.

New therapeutic strategies to ameliorate IR have been tried with modulating intestinal microbiota\textsuperscript{21}, autophagy\textsuperscript{22}, and cell therapy with MSCs\textsuperscript{23–25}. These reports present remarkable alleviation of IR by MSCs in a typical T2DM rats which has proceeded to a late state of disease. However, whether MSCs could prevent the deterioration of hyperinsulinemia at early stage of T2DM is not clear.

Therefore, we aimed to investigate the effect of bone marrow-derived MSCs (BM-MSCs) on hyperinsulinemia at the early stage of T2DM. The results suggested that early transplantation of MSCs holds a promising role in controlling the progress of T2DM at early stage.

**Materials and Methods**

**Animals and Sample Collection**

Male Sprague-Dawley rats (approximately 200 g, HFK bioscience, Beijing, China) were used for all studies. All experimental procedures were approved by Tongji Medical College, Huazhong University of Science and Technology Institutional Animal Care and Use Committee (2016IACUC number, 644). All efforts were made to reduce the number of animals tested and their suffering. Animals were fed either a normal chow diet or a high-fat diet (Animal Center, Huazhong University of Science and Technology)\textsuperscript{26} for 4 wk. On experimental days, food was removed at 8 AM and blood was sampled 4 h later for analysis for insulin (Rat INS (Insulin) ELISA Kit, Elabscience, Wuhan, China), proinsulin (Rat PI (Proinsulin) ELISA Kit, Elabscience), triglyceride (TG) (glycerine phosphate oxidase peroxidase method, JCBio, Wuhan, China), low-density lipoprotein (LDL kit, JCBio), T-CHO (glucose oxidase-phenol amino phenazone method, JCBio), alanine aminotransferase (ALT) (microplate method, JCBio), and aspartate aminotransferase (AST) (microplate method, JCBio). Tail blood was directly subjected to glucose meter (ACCU-CHEK, Roche, Basel, Switzerland) for glucose concentration, or collected.

Oral glucose tolerance test (OGTT) was assessed when animals were fasted overnight to determine their glucose response to the oral administration (by gavage) of a solution of 20% glucose (2 g/kg) before (time 0) and 30, 60, and 120 min after administration of glucose\textsuperscript{26}.

**BM-MSC Preparation and Administration**

BM-MSCs were isolated following a previously described method\textsuperscript{27}. Briefly, rats were sacrificed and their hind limbs were harvested, bone marrow was flushed out and collected in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Grand Island, NY, USA) supplied with 10% fetal bovine serum (Gibco). Thereafter cells were cultured in a 25-cm\textsuperscript{2} flask in 5% CO\textsubscript{2} incubator at 37 °C. Nonadherent cells were removed after 24 h and adherent cells were passaged every week using 0.05% trypsin. About 5 × 10\textsuperscript{5} (for high concentration) or 10\textsuperscript{5} (for low concentration) cells between passages 3 to 6 were intravenously injected via tail vein.

**Histological and Immunohistochemical Staining**

Pancreases were freshly removed from the rats, 6-μm sections were cut immediately, and fixed with acetone for hematoxylin-eosin (H&E) staining using standard techniques. Some sections were subjected to immunohistochemical staining (animals were previously intravenously injected with BrdU for 3 days). After the process consisting of 10 min of fixation with acetone, 2 h of permeabilization with 0.3% Triton X-100 (Sigma, St. Louis, MO, USA), and 1 h of blocking with 3% albumin from bovine serum (BSA) (Gibco) at room temperature, the sections were incubated with the primary antibody rabbit anti-rat BrdU (1:100, Proteintech Group, Chicago, IL, USA) overnight at 4 °C, followed by a further incubation with the secondary antibody goat anti-rabbit IgG-TRITC (1:50, Proteintech Group) for 60 min at room temperature to detect the cycling cells in the pancreas. 6-Diamidino-2-phenylindole (DAPI, Beyotime, Shanghai, China) was used to stain the nuclei for 10 min. The pictures were captured using Immuno Floure (Olympus, Tokyo, Japan).

**Western Blot**

Protein extracts of liver were prepared in radio immunoprecipitation assay (RIPA) buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and 1 mM phenylmethylsulfonyl fluoride) according to the standard methods (Beyotime, Shanghai, China). Protein concentration was determined using the bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, Rockland, ME, USA). About 30 μg of total protein per lane was resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane. Primary antibody rabbit anti-β-actin antibody (1:10,000, TDY Biotech Co., Ltd, Beijing, China), rabbit anti-GLUT4 antibody (1:1000, Abcam, Cambridge, MA, USA), rabbit anti-p-AKT (1:1000, Cell Signaling Technology, Inc., Danvers, MA, USA), rabbit anti-p-AKT (1:1000, Cell Signaling Technology, Inc.), rabbit anti-p-insulin receptor substrate (IRS)-1 (1:500, Abcam), rabbit anti-IRS-1 (1:1000, Cell Signaling Technology, Inc.), rabbit anti-IL-6 (1:1000, Affibiotec, Changzhou, China), and rabbit anti-TNFα (1:1000, Abcam) were diluted and detected using HRP-goat anti-rabbit IgG (ASPen, Wuhan, China) and the enhanced chemiluminescent reagent (ECL; Pierce Biotechnology).
Immunoreactive bands were detected using Kodak BioMax ML film (Kodak, Rochester, New York, USA). The results were characteristic of at least three independent experiments.

**Statistical Analysis**

All results are presented as mean ± SEM. Treatments were compared using Student’s unpaired t test or one-way ANOVA with least significant difference post hoc test. A $P < 0.05$ was considered to be statistically significant.

**Results**

**Characteristics of the High-Fat-Fed Induced Hyperglycemia and Hyperinsulinemia Rat Models**

Success of high-fat-fed hyperinsulinemia rat model was confirmed by checking blood glucose, insulin, and proinsulin, respectively (Fig. 1). Four weeks after high fat food, animals were subjected to OGTT. We measured basal blood glucose (normal diet: $4.80 ± 0.58$ mM vs high fat diet: $13.23 ± 0.24$ mM) as well as blood glucose levels 1 h after
oral administration of glucose (normal diet: 7.40 ± 0.12 mM vs high-fat diet: 20.66 ± 0.20 mM) and found that in high-fat diet rats levels were increased by 150% more than normal diet rats (Fig. 1A). Significant insulin (normal diet: 9.57 ± 0.62 ng/ml vs high fat diet: 54.84 ± 0.99 ng/ml) and proinsulin (normal diet: 1.04 ± 0.07 ng/ml vs high fat diet: 2.74 ± 0.09 ng/ml) elevations were also detected (Fig. 1B, C). These data validated that the high-fat diet rats were clinically in early stage of T2DM. Moreover, in these high-fat diet rats, significant deterioration in lipometabolic disorders and abnormal ALT/AST concentration were observed (Fig. 1D, E).

**BM-MSCs Attenuated the Increased Insulin and Glucose as Well as Restored Lipometabolic Disorder in High-Fat-Fed Rats**

Notably, tail vein injection of MSCs induced a significant decrease in both insulin and glucose levels in high-fat-fed rats (Fig. 2A, B). Both $10^5$ MSCs and $5 \times 10^5$ MSCs significantly attenuated fat-fed induced hyperinsulinemia and hyperglycemia (Fig. 2B, C); $5 \times 10^5$ MSCs exerted a greater effect, while incompletely reversed the abnormal OGTT and insulin concentration. Lipometabolic disorders and concentration of AST/ALT were successfully restored to the normal level by $5 \times 10^5$ MSCs.

**BM-MSCs Favored the Histological Structure Recovery in High-Fat-Fed Hyperinsulinemia Rat Model**

Fat-fed diet rats had bigger islets (Fig. 3B) than normal diet rats (Fig. 3A) but with irregular morphology and disruption of basement membrane. Lipid accumulation was observed in some islet cells (Fig. 3B). Treatments with $10^5$ MSCs remarkably favored the recovery of the islets and the islet cells. Although abnormal morphology of islets was only partially rescued, lipid in the cells decreased significantly (Fig. 3C). Treatment with $5 \times 10^5$ MSCs exhibited better therapeutic
effects, where the islets had normal morphology and lipid was almost undetectable in the islet cells (Fig. 3D). Further immunohistochemical staining of BrdU⁺ cells in the pancreas revealed that BM-MSCs countervailed high-fat-fed induced damage to proliferation ability (Fig. 4).

**BM-MSCs Reversed the Abnormal Insulin Signaling Transduction and Inflammation in High-Fat-Fed Rat Liver**

Protein extracts of liver were used to investigate the influence of BM-MSCs on insulin signaling transduction. High fat-fed rats had less GLUT4 and downregulation of phosphorylated insulin receptor substrate 1 (p-IRS-1) and protein kinase Akt (p-AKT). Administration of BM-MSCs resulted in an increase of GLUT4 expression and enhanced p-IRS-1 and Akt (Fig. 5A–D). Additionally, a high fat-fed induced upregulation of proinflammatory cytokines TNFα and IL-6, which was reversed by BM-MSCs (Fig. 5E–G). These data suggest that BM-MSCs can effectively potentiate the transduction of insulin signaling and inhibit the inflammation in insulin target tissues.

**Discussion**

A high-caloric diet has been broadly characterized as the trigger of T2DM, and T2DM accounts for 90%–95% of all DM cases, IR being the typical symptom and mechanism at the early stage of dietary-induced T2DM. High-fat-induced IR could generally associate with alterations in lipid cellular intake and accumulation, followed by disorders of the metabolism of β-cells, stroke, and other diseases. Here in our model, the high fat diet for 4 wk successfully induced hyperinsulinemia and elevation of blood glucose concentration, which was associated with lipometabolic disorders and rising ALT/AST. With this model, we showed that the intervention of MSCs at early stage of T2DM could significantly lead to decline of insulin/glucose as well as rescue lipometabolic disorders and liver dysfunction. A much lower cell dose (5 × 10⁵; vs 2 × 10⁶ cells in typical T2DM model) induced remarkable effects, which suggested an economic time window for application of MSCs in T2DM.

MSCs harbor great potential to become a routine therapeutic measure for T2DM, partially due to reversing IR.
Previous studies have shown that infusion of MSCs ameliorates hyperglycemia by alleviating IR in T2DM rats. Consistently, we found that in vivo transplantation of BM-MSCs attenuated increase in insulin and glucose resulting from a high-fat diet. It was notable that such therapeutic potential was not observed in a typical T2DM model induced by both high-fat diet and injection of streptozotocin, but in a high-fat diet triggered model. This strongly suggests early transplantation of MSCs could serve as a better strategy than have been proposed by previous studies to restore pancreatic or multiple organ dysfunction at later stage of T2DM.

IR could produce hyperinsulinemia, this in turn induces multiple organic dysfunction due to an abnormal intake of lipid and lipid accumulation in cells. We found that MSCs restored lipometabolic disorders and liver dysfunction, as evidenced by the concentration of LDL/TG/TC and AST/ALT. More importantly, high-fat diet caused lipid accumulation in islet cells and disruption of the islet basement membrane; BM-MSCs favored the histological structure recovery, and obviously improved the proliferation potential of islet cells. These findings indicated that the potential risk of T2DM for other organs as well as the pancreas could be prevented if MSC transplantation is exerted at early stage of T2DM.

GLUT4 and phosphorylation of IRS-1 (p-IRS-1) and AKT (p-AK) are crucial for conferring insulin-signaling transduction, and glucose uptake therefore related intensively to IR. Here in our high fat-fed induced IR model, BM-MSCs successfully enhanced GLUT4, p-IRS-1, and p-AKT, which is similar to the findings in typical T2DM model with MSC treatment. A lot of evidence has shown that chronic activation of proinflammatory pathways within insulin target cells could lead to IR. We found that BM-MSC remarkably reversed the upregulation of IL-6 and TNFα in the liver. These observations suggested that both the insulin-signaling pathway and proinflammatory pathways are involved in the favorable function of BM-MSCs in high fat-fed induced IR.

Due to the increase in associated risk factors, such as being overweight or obese, the global prevalence of (age-standardized) DM has been rising dramatically and it might become reality that 1 adult in every 10 will have diabetes in 2040. Our study proposed a new strategy with MSC-based cell therapy for T2DM, i.e., MSC transplantation during hyperinsulinemia before onset of diabetes could prevent most possible risks of T2DM for patients.

It is the limitation of our study that we did not go further to investigate the detailed mechanisms for MSCs to reverse...
IR in the early stage of T2DM. The widely accepted idea is that MSC infusion with host cells is one of the possibilities\textsuperscript{24}. This could also be the underlying phenomenon in our study. Future work is necessary to validate it and to explore other possible mechanisms.

**Data Availability**

All the data used to support the findings of this study are included within the article files.

**Ethical Approval**

Ethical approval to report this case was obtained from Tongji Medical College, Huazhong University of Science and Technology Institutional Animal Care and Use Committee (Approval: 2016IACUC number, 644).

**Statement of Human and Animal Rights**

All procedures in this study were conducted in accordance with the Tongji Medical College, Huazhong University of Science and Technology Institutional Animal Care and Use Committee (Approval: 2016IACUC number, 644) approved protocols.

**Statement of Informed Consent**

There are no human subjects in this article and informed consent is not applicable.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We

---

**Fig. 5.** BM-MSCs reversed insulin signaling transduction and inflammation in a high fat-fed rat liver. Western blot analysis on GLUT4, p-IRS-1, and p-AKT (A), and proinflammatory cytokines IL-6 and TNF\textalpha{} (E). Statistical data (B–D, F–G) revealed that administration of MSCs successfully reversed the abnormal expression of these proteins in fat-fed rat model. *\ p < 0.01 vs control, \#p < 0.05 and \#\#p < 0.01 vs fat-fed. BM-MSCs, bone marrow-derived mesenchymal stem cells; MSCs, mesenchymal stem cells.
gratefully acknowledge funding from the National Natural Science Foundation of China (NSFC, 81801922) and Chronic Wound & Diabetes Medical Clinical Research Center Foundation of Hubei provincial China (2018BCC340).

**ORCID iD**
Binghui Li https://orcid.org/0000-0001-7962-186X

**References**
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahan SY, Alvarado M, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
2. Carofozo C, Iazzetta N, Camocardi A, Pacilio M, Iodice C, Minutolo R, De Nicola L, Conte G. Anti-diabetes and chronic kidney disease [in Italian]. G Ital Nefrol. 2015;32(5):1112–1114.
3. Esteves J, Laranjeira AF, Roggia MF, Dalpizol M, Scocco C, Kramer CK, Azevedo MJ, Canani LH. Diabetic retinopathy risk factors [in Portuguese]. Arq Bras Endocrinol Metabol. 2008;52(3):431–441.
4. Kraegen EW, James DE, Storlien LH, Burleigh KM, Chisholm DJ. In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: assessment by euglycaemic clamp plus deoxyglucose administration. Diabetologia. 1986;29(3):192–198.
5. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes. 1991;40(11):1397–1403.
6. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol. 1986;251(5 Pt 1):E576–583.
7. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type ii diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113(12):909–915.
8. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl. 2004(143):9–21.
9. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110.
10. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005;307(5708):380–384.
11. Kornicka K, Houston J, Marycz K. Dysfunction of mesenchymal stem cells isolated from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and autophagy may limit their potential therapeutic use. Stem Cell Rev Rep. 2018;14(3):337–345.
12. Piya MK, Tahrania AA, Barnett AH. Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol. 2010;70(5):631–644.
13. Holmboe ES. Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. JAMA. 2002;287(3):373–376.
14. Si YL, Zhao YL, Hao HJ, Fu XB, Han WD. Mscs: biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev. 2011;10(1):93–103.
15. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med. 2010;16(5):203–209.
16. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5(1):94–100.
17. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008;57(7):1759–1767.
18. Lee RH, Soo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic nod/scid mice. Proc Natl Acad Sci U S A. 2006;103(46):17438–17443.
19. Shree N, Bhonde RR. Conditioned media from adipose tissue derived mesenchymal stem cells reverse insulin resistance in cellular models. J Cell Biochem. 2017;118(8):2037–2043.
20. Xie Z, Hao H, Tong C, Cheng Y, Liu J, Pang Y, Si Y, Guo Y, Zang L, Mu Y, Han W. Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells. 2016;34(3):627–639.
21. Dos Reis SA, do Carmo Gouveia Peluzio M, Bressan J. The use of antimicrobials as adjuvant therapy for the treatment of obesity and insulin resistance: effects and associated mechanisms. Diabetes Metab Res Rev. 2018;34(6):e3014.
22. Zhao K, Hao H, Liu J, Tong C, Cheng Y, Xie Z, Zang L, Mu Y, Han W. Bone marrow-derived mesenchymal stem cells ameliorate chronic high glucose-induced β-cell injury through modulation of autophagy. Cell Death Dis. 2015;6(9):e1885.
23. Tsatsoulis A. The role of insulin resistance/hyperinsulinism on the rising trend of thyroid and adrenal nodular disease in the current environment. J Clin Med. 2018;7(3):37.
24. Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, Shen J, Cheng Y, Fu X, Han W. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes. 2012;61(6):1616–1625.
25. Sun X, Hao H, Han Q, Song X, Liu J, Dong L, Han W, Mu Y. Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing nrp3 inflammasome-mediated inflammation in type 2 diabetes rats. Stem Cell Res Ther. 2017;8(1):241–241.
26. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadoibs TM, Reaven GM. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism. 2000;49(11):1390–1394.
27. Seo N, Lee SH, Ju KW, Woo J, Kim B, Kim S, Jahng JW, Lee JH. Low-frequency pulsed electromagnetic field pretreated bone marrow-derived mesenchymal stem cells promote the
regeneration of crush-injured rat mental nerve. Neural Regen Res 2018;13(1):145–153.

28. Acosta-Montano P, Garcia-Gonzalez V. Effects of dietary fatty acids in pancreatic beta cell metabolism, implications in homeostasis. Nutrients 2018;10(4):393.

29. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. Idf diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128(1):40–50.

30. Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes. 2017;8(4):120–129.

31. Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2013;36(6):1779–1788.

32. Roever L, Resende ES, Diniz ALD, Penha-Silva N, O’Connell JL, Gomes PFS, Zanetti HR, Roerver-Borges AS, Veloso FC, Fidale TM, Casella-Filho A, et al. Metabolic syndrome and risk of stroke: protocol for an update systematic review and meta-analysis. Medicine (Baltimore). 2018;97(15):e9862.

33. Moon KC, Lee JS, Han SK, Lee HW, Dhong ES. Effects of human umbilical cord blood-derived mesenchymal stromal cells and dermal fibroblasts on diabetic wound healing. Cytotherapy. 2017;19(7):821–828.

34. Daltro PS, Barreto BC, Silva PG, Neto PC, Sousa Filho PHF, Santana Neta D, Carvalho GB, Silva DN, Paredes BD, de Alcantara AC, Couto RD, et al. Therapy with mesenchymal stromal cells or conditioned medium reverse cardiac alterations in a high-fat diet-induced obesity model. Cytotherapy. 2017;19(10):1176–1188.

35. Lin HV, Ren H, Samuel VT, Lee HY, Lu TY, Shulman GI, Accili D. Diabetes in mice with selective impairment of insulin action in GLUT4-expressing tissues. Diabetes. 2011;60(3):700–709.

36. Waller AP, Burns TA, Mudge MC, Belknap JK, Lacombe VA. Insulin resistance selectively alters cell-surface glucose transporters but not their total protein expression in equine skeletal muscle. J Vet Intern Med. 2011;25(2):315–321.

37. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72(1):219–246.